Introduction
A woman is born with about 2 million primordial follicles, yet by the onset of menarche only about 400,000 follicles are left due to natural follicular atresia. As a woman reaches her mid-30s the pace of oocyte depletion begins to increase and by the time she reaches her late 30s, the number of follicles declines to approximately 25,000, concomitant with a significant increase in miscarriage rate. The term "ovarian reserve" has traditionally been used to describe a woman's reproductive potentiale specifically, the number and quality of oocytes she possesses. 1 However, commonly used ovarian reserve markers serve as a proxy for oocyte quantity but are considered poor predictors of oocyte quality. Therefore, modern usage of the term pertains to the quantity of remaining oocytes rather than oocyte quality, for which age still remains the best predictor. Diminished ovarian reserve (DOR) describes women of reproductive age having menses whose response to ovarian stimulation or fecundity is reduced compared with women of comparable age. 1 It is distinct from menopause or premature ovarian insufficiency. Ovarian reserve is a complex clinical phenomenon influenced by age, genetics, and environmental variables. 2 The decline in a woman's ovarian reserve with time is irreversible and the rate at which women lose primordial follicles varies considerably, with wide variation regarding the onset of sterility and timing of the menopausal transition. Although it is challenging to predict the rate of an individual's ovarian reserve decline, clinicians are often asked for advice about fertility potential and/or recommendations regarding the pursuit of fertility treatment options. Over the past few years, there have been several comprehensive reviews on ovarian reserve tests that focused mainly on ovarian response prediction in the context of assisted reproductive technology (ART). [3] [4] [5] [6] The purpose of this review is to summarize the state-ofthe-art of ovarian reserve testing, providing a practical guide for the obstetrician/gynecologist generalist and reproductive endocrinologist.
What makes a reliable ovarian reserve test?
Ovarian reserve tests started to emerge during the rise of ART in the late 1980s to predict both responsiveness to superovulation drugs and the odds of pregnancy with treatment. They include both biochemical basal and provocative tests and ultrasound imaging of the ovaries. The first test to be introduced was day-3 follicle-stimulating hormone (FSH) (1988), followed by clomiphene citrate challenge test (CCCT) (1989), gonadotropin releasing-hormone (GnRH) agonist (1989), inhibin B (1997),
Ovarian reserve is a complex clinical phenomenon influenced by age, genetics, and environmental variables. Although it is challenging to predict the rate of an individual's ovarian reserve decline, clinicians are often asked for advice about fertility potential and/ or recommendations regarding the pursuit of fertility treatment options. The purpose of this review is to summarize the state-of-the-art of ovarian reserve testing, providing a guide for the obstetrician/gynecologist generalist and reproductive endocrinologist. The ideal ovarian reserve test should be convenient, be reproducible, display little if any intracycle and intercycle variability, and demonstrate high specificity to minimize the risk of wrongly diagnosing women as having diminished ovarian reserve and accurately identify those at greatest risk of developing ovarian hyperstimulation prior to fertility treatment. Evaluation of ovarian reserve can help to identify patients who will have poor response or hyperresponse to ovarian stimulation for assisted reproductive technology. Ovarian reserve testing should allow individualization of treatment protocols to achieve optimal response while minimizing safety risks. Ovarian reserve testing may inform patients regarding their reproductive lifespan and menopausal timing as well as aid in the counselling and selection of treatment for female cancer patients of reproductive age who receive gonadotoxic therapy. In addition, it may aid in establishing the diagnosis of polycystic ovary syndrome and provide insight into its severity. While there is currently no perfect ovarian reserve test, both antral follicular count and antimü llerian hormone have good predictive value and are superior to day-3 follicle-stimulating hormone. The convenience of untimed sampling, age-specific values, availability of an automated platform, and potential standardization of antimü llerian hormone assay make this test the preferred biomarker for the evaluation of ovarian reserve in women.
antral follicular count (AFC) (1997), and antimüllerian hormone (AMH) (2002) . Most of these measures, however, have poor predictive value, often because they are indirect measures of ovarian reserve (eg, FSH, CCCT, GnRH agonist) or have substantial intracycle or intercycle variability (eg, FSH). [7] [8] [9] The provocative tests (CCCT and GnRH agonist) have been virtually abandoned due to expense and inconvenience as they require >1 timed patient visit. Today, the markers most often used in clinical practice are the basal testseFSH, AFC, and AMHe which are discussed in detail below. The other biochemical markers that have proven to be less useful are reviewed in detail elsewhere. 10 The purpose of using ovarian reserve testing as a screening test is to identify infertility patients at risk for DOR, who are more likely to have poor response to gonadotropin stimulation and less likely to achieve pregnancy with ART or ovulation induction. It can also contribute to making ovulation induction safer by identifying and potentially precluding those at greatest risk of developing ovarian hyperstimulation syndrome (OHSS), a life-threatening iatrogenic complication, prior to receiving such therapy. The ideal ovarian reserve test should be affordable, noninvasive, and rapidly interpretable. It should also be reproducible and display minimal variability within the menstrual cycle and between cycles. Moreover, it should be able to detect the decline in ovarian reserve at an early enough stage such that timely interventions could be pursued if desired. Lastly, it should have validity, ie, good sensitivity and specificity. From a clinical standpoint, the threshold for considering a test abnormal for DOR should have high specificity. This would minimize the number of patients with normal ovarian reserve wrongly categorized as DOR. Importantly, this would avoid unnecessary treatments in patients with normal ovarian reserve or recommendations for oocyte donation or adoption in those patients who should be able to conceive on their own. On the other hand, optimizing specificity sacrifices sensitivity and the ability to identify all women with DOR. Moreover, it is important to emphasize that ovarian reserve tests have limitations and should not be used as sole criteria to deny patients access to ART or other treatments. Evidence of DOR does not necessarily mean inability to conceive, only that it may be less likely. Furthermore, identification of those at greatest risk of OHSS prior to ovulation induction would allow for judicious selection and use of gonadotropins or oral fertility agents and the deployment of additional available strategies for OHSS prevention (GnRH agonist trigger, cabergoline, freeze all) as well as patient appropriate counseling to set realistic expectations prior to beginning treatment.
Early follicular follicle-stimulating hormone The use of early follicular phase (basal) FSH as a marker of ovarian reserve was proposed almost 30 years ago, as a tool to predict ovarian response to in vitro fertilization (IVF). [11] [12] [13] This test is an indirect assessment of ovarian reserve and is based on the feedback inhibition of FSH pituitary secretion by ovarian factors. At the beginning of the menstrual cycle, estradiol and inhibin B levels reach a nadir, offering a glimpse to the unsuppressed hypothalamuspituitary-ovarian axis before levels of these ovarian hormones rise and inhibit FSH secretion. Women with normal ovarian reserve have sufficient production of ovarian hormones at this early stage of the menstrual cycle to maintain FSH levels within normal range. In contrast, elevation of FSH at this stage of the menstrual cycle indicates poor production of ovarian hormones by diminishing the ovarian follicular pool consistent with DOR. However, basal FSH testing has several major limitations including significant intercycle and intracycle variability that limits its reliability, 7, 8 it requires a functional hypothalamus-pituitaryovarian axis, and it is not adequately sensitive for clinical utilityeonly elevations carrying significance. The latter limitation is the reason that basal FSH test must be combined with estradiol, which enhances the sensitivity of early follicular FSH testing. Combining basal FSH with estradiol is more meaningful since even normal-range FSH can imply DOR in the setting of elevated basal estradiol. In women with declining ovarian reserve, premature elevations in FSH in the early follicular phase drive estradiol levels higher, which, in turn, may lead to increased negative feedback on pituitary FSH production thus masking abnormal FSH elevation, which would otherwise reveal DOR. Measurement of both FSH and estradiol on cycle day 3 may therefore help decrease the incidence of falseenegative testing. Despite its limitations, FSH is commonly used as an ovarian reserve test, and high values have been associated with both poor ovarian response and failure to achieve pregnancy.
14 FSH has particularly high specificity (45-100%) for predicting poor response to ovarian stimulation (usually defined as 4 retrieved oocytes) using multiple cut-off points >10 IU/L (10-20 IU/L), but its sensitivity is generally poor (11-86%) and decreases with increasing FSH cut-off points. 14, 15 In terms of predicting failure to conceive, FSH testing is still specific (50-100%) but much less sensitive (3-65%) using similar cut-offs (Table 1) . 14, 15 This test is still clinically useful since an abnormally elevated FSH result is almost synonymous with late DOR (high positive predictive value), but the majority of women who are tested (including those with DOR) will have a normal test result (low negative predictive value). Moreover, a single abnormal FSH value in a woman <40 years of age may not predict a poor response to stimulation or failure to achieve pregnancy, 16 and should prompt repeat testing. In terms of OHSS, FSH has no predictive value for this complication.
Antimü llerian hormone AMH is a glycoprotein that belongs to the transforming growth factor-b superfamily and is produced in the female exclusively by granulosa cells of small and large preantral and small antral follicles. 4 Although AMH was first noted to Expert Reviews ajog.org be present in follicular fluid in 1993, 17 its function was incompletely understood. It was later that its clinical utility as an ovarian reserve marker was first reported 18 following studies of AMHe deficient mice demonstrating accelerated atresia when the AMH gene was deficient. 19, 20 While lack of AMH does not seem to affect fertility in female mice, increased recruitment of primordial follicles leads to early depletion in ovaries of AMHedeficient mice. 19, 20 The ovary begins producing AMH in utero at about 36 weeks of gestation, 21 its levels rise in young women beginning in adolescence and peak at about 25 years of age, then gradually decline until reaching undetectable levels a few years prior to menopause. AMH acts as a leading negative paracrine regulator of early folliculogenesis as it inhibits recruitment of primary follicles from the primordial pool, prevents selection of follicles by FSH, and inhibits aromatase. [22] [23] [24] Since AMH is expressed during normal early folliculogenesis (secreted by early follicles up to 6 mm), it is relatively independent of gonadotropins circulating at physiologic levels and allows for testing anytime throughout the cycle. While several earlier studies suggested that AMH is relatively stable throughout the menstrual cycle in normoovulatory AFC, antral follicular count; AMH, antimü llerian hormone; AUC, area under the curve; CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; FSH, follicle-stimulating hormone; HPO, hypothalamus-pituitary-ovarian; OHSS, ovarian hyperstimulation syndrome.
a Cut-offs used for calculating sensitivities and specificities for prediction of poor ovarian response; b Cut-offs used for calculating sensitivities and specificities for prediction of nonpregnancy.
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women, [25] [26] [27] [28] [29] other studies noted significant fluctuations within 1 menstrual cycle. [30] [31] [32] [33] While this issue remains highly debated, evidence suggests that if significant fluctuations in AMH levels do occur, they are limited to younger women 34 and those with high basal AMH levels, 31 and that in patients with low ovarian reserve (usually aged women) AMH fluctuations have little clinical relevance. 31, 34 Moreover, the random and noncyclic fluctuations in AMH indicate that measuring the hormone on a fixed day of the menstrual cycle would not yield any advantage to random assessment. 31 Sensitivity and specificity Among all ovarian reserve tests, AMH is considered the earliest and most sensitive. It correlates strongly with the primordial follicle pool, has an inverse correlation with chronologic age, 35, 36 reliably predicts ovarian response in ART, 37, 38 and is predictive of the timing of the onset of menopause. [39] [40] [41] In a systematic review of studies in women undergoing controlled ovarian stimulation with gonadotropins, low AMH cutoff points (0.1-1.66 ng/mL) have been found to have sensitivities ranging between 44-97% and specificities ranging between 41-100% for prediction of poor ovarian response. 4 In a meta-analysis that included 28 studies, AMH was found to have good predictive ability for poor ovarian response, with an area under the curve (AUC) of 0.78. 42 Moreover, AMH has remarkable utility in predicting ovarian hyperstimulation to gonadotropin stimulation, with sensitivities ranging from 53-90.5% and specificities ranging from 70-94.9% when using cut-off values of 3.36-5.0 ng/mL. 4 However, despite its strong correlation with ovarian response to stimulation in ART, AMH is a poor predictor of nonpregnancy with sensitivities between 19-66%, and specificities between 55-89% when using cut-offs ranging from <0.1-1.66 ng/mL (Table 1) . 3 Notably, a recent study of the Society for Assisted Reproductive Technology database found that while women with ultralow AMH (<0.16 ng/ mL) had 54% cycle cancellation rate, the overall live birth rate per cycle start was 9.5%, 43 supporting the notion that denying infertility treatment solely on the basis of undetectable AMH is not advisable. Similarly, AMH is a poor predictor of pregnancy and live birth following ART, with 2 recent meta-analyses showing the AUC for AMH as predictor of clinical pregnancy and live birth to be 0.63 and 0.61, respectively. 44, 45 The sensitivities and specificities for AMH in predicting clinical pregnancy ranged from 34.4-86.2% and 26-78.5%, respectively, with cut-offs ranging between 1.0-3.22 ng/mL (Table 1) . 45 Moreover, AMH values were not associated with fecundability in unassisted conceptions in a cohort of fecund women with a history of 1 or 2 losses. 46 These data are consistent with AMH being a predictive marker of oocyte quantity but not quality.
Limitations
The main limitations of the AMH test relate to assay variability and lack of standardized international assay. Prior to 2010, 2 different assays were used; the European and US assays were developed independently with different antibodies and reported very different results, using different units. That problem was thought to be resolved by the manufacture of both enzymelinked immunosorbent assays by the same company and the development of a new assay (Gen II, Beckman Coulter Inc, Brea, CA) that combines the best features of both. 47 However, several studies have demonstrated intraassay/ interassay differences, between laboratory differences, and sample stability and storage issues related to the Gen II assay. 48 Automated AMH assay platforms offer improvement of greater precision (4-fold), faster turnaround time (18 minutes vs 6 hours), and greater sensitivity (10-fold) compared to current enzyme-linked immunosorbent assay based assays. 49 [52] [53] [54] [55] [56] [57] [58] and are informative for the population of women presenting to fertility clinics. Thus, the reference values are age appropriate and not referenced to a general population of women independent of age. Such values may be analogous to a Z score (compared to an agematched cohort) for ovarian reserve. As a general guideline we consider the lower limit of age-appropriate serum AMH values for the following in 5-year age intervals to be approximately: 0.5 ng/mL for 45 years, 1 ng/mL for 40 years, 1.5 ng/ mL for 35 years, 2.5 ng/mL for 30 years, and 3.0 ng/mL for 25 years. These are likely to be conservative estimates as recent iterations of the most widely used AMH assay, Gen II, report about 30-40% higher mean values compared to these guidelines. So, in practice, if a 35-yearold woman presents with an AMH of 1 ng/mL this may be of concern as one would have conservatively expected an AMH value of at least 1.5 ng/mL. An AMH of 1 ng/mL is what one might conservatively expect from a 40-year-old woman. Such a lower observed value in the context of the rest of a patient's history (ie, smoking or early onset of menopause of her mother) may point to taking a more expeditious approach to her fertility treatment depending on her expectations for conceiving >1 child in the future.
Factors affecting AMH results
In addition, when interpreting a patient's AMH test results it is important for the clinician to consider the effects of possible influencing factors to avoid inaccurate assessment of ovarian reserve. 71 and obesity have been associated with lower AMH levels, although the effect of obesity is inconsistent among studies. 61, 63, 66, [72] [73] [74] [75] [76] [77] [78] Antral follicular count AFC is the sum of follicles in both ovaries as observed on ultrasound in the early follicular phase (day 2-4) of the menstrual cycle. Antral follicles are defined as those measuring 2-10 mm in largest mean diameter on 2-dimensional plane. AFC is easy to carry out, provides an immediate result, and has good intercycle reliability and good interobserver reliability when measured in experienced centers using a minimal number of sonographers. Its precision is compromised with overweight and obese individuals or when using multiple sonographers. 3, 15 As suggested by a meta-analysis, a low AFC is associated with poor ovarian response to ovarian stimulation during IVF, but has poor predictability for pregnancy. Across general IVF study populations of patients at both low and high risk of DOR, low AFC cut-off points of 3-4 follicles (both ovaries combined) are highly specific (73-97%) for predicting poor ovarian response (<3-4 oocytes, cycle cancellation) but have low sensitivity (9-73%). 15 In another meta-analysis, the AUC for AFC in predicting poor ovarian response was 0.76. 42 In terms of nonpregnancy prediction, AFC is still specific (64-98%) but much less sensitive (7-34%). 15 There are several limitations to AFC measurement. It must be carried out at the beginning of a cycle due to intracycle variation. In addition, AFC has inherent variability related to technology and interobserver variability. Significant variation in AFC has been observed both between as well as within centers. 3, 15 This variation may be caused by differences in operator training, number of sonographers, methodology as well as criteria for measuring antral follicles, and differences in ultrasound technology (eg, resolution of ultrasound, 2-vs 3-dimensional). In addition, AFC has a tendency to overestimate the number of FSH-sensitive follicles and oocytes retrieved since it inevitably also measures atretic follicles of the same size.
79, 80 Moreover, greater intracycle and intercycle variation has been observed in overweight and obese women, limiting the predictive value of AFC in this subpopulation of women, which is ever increasing in industrial nations. 3, 15 In terms of OHSS prediction, both AFC and AMH demonstrate strong predictive value for predicting those at greatest risk for OHSS.
Which ovarian reserve test should I choose?
A large body of evidence has demonstrated greater clinical value of AMH and AFC compared to FSH. 5 AMH will decline years prior to a rise in FSH and thus, is an earlier, more sensitive realtime biomarker of ovarian reserve. It is now well recognized that AMH is a direct product of both cumulus and mural granulosa cells from preantral and small antral follicles during early folliculogenesis. AMH has a greater correlation with the primordial follicle pool (egg supply) compared to ovarian markers produced by follicles during late folliculogenesis (inhibin B and estradiol) and compared to indirect markers such as FSH. In comparison, AFC measures only antral follicles that can be visualized by ultrasound in 86 Interestingly, the authors found that at age 34-42 years, normal AMH carried better prognosis than normal FSH in terms of oocyte yield, while at age >42 years normal FSH was associated with better prognosis than normal AMH. For both age ranges, the group with both normal AMH and FSH always had the best prognosis while the one with both values abnormal had the worst prognosis. 86 A different study assessing discordance between AMH and AFC in patients undergoing IVF found that 32.3% of women had discordant results. 87 The discordant groups with low to normal ovarian reserve had ovarian responsiveness intermediate between those with concordantly low and concordantly normal AMH and AFC. Likewise the discordant groups with normal to high ovarian reserve had ovarian responsiveness intermediate between those with concordantly normal and concordantly high AMH and AFC. In addition, within each AFC category, those with higher AMH had significantly higher number of oocytes retrieved. 87 Therefore, when ovarian reserve tests fall into discordant categories, it would be reasonable to consider the ovarian Who should get ovarian reserve testing and how to use it in clinical practice? Historically, ovarian reserve testing was used for prediction of ovarian response to controlled ovarian stimulation in ART, helping to identify patients who are more likely to have a poor response or hyperresponse to gonadotropins. Over the past decade, since the discovery of AMH as an ovarian reserve marker, it has been increasingly recognized that AMH testing may have utility for a variety of other clinical applications in reproductive medicine (Table 3) . 48, 88 Assisted reproductive technology The usefulness of AMH in predicting ovarian response to controlled ovarian stimulation in ART has led to AMHbased pretreatment counselling and individualization of ART stimulation protocols including choice of regimens and dose adjustments. 38, 56, 89, 90 The following general guidelines are useful for clinical practice: AMH <0.5 ng/mL predicts poor ovarian response in IVF with yield of 4 oocytes. 4, 91 In such cases, a discussion with the patient about the short window of opportunity to conceive seems warranted. 5 Ovarian stimulation protocols in these patients should include the ones reserved for the most challenging patients (ie, using microdose GnRH agonist flare with high starting dose or late luteal estradiol priming with or without late luteal presuppression antagonist with high starting dose of gonadotropins). AMH level !1.0 ng/mL but 3.5 ng/ mL if age appropriate is consistent with normal ovarian response to ovarian stimulation. IVF protocols for these patients should include standard GnRH agonist or antagonist, with adjustments based on agespecific values. [51] [52] [53] [54] [55] [56] [57] [58] AMH >3.5 ng/mL predicts hyperresponse to ovarian stimulation and is associated with significantly higher risk of OHSS. 4 Such patients would benefit from mild lower dose regimens, and protocols that minimize OHSS risk (eg, GnRH antagonist with GnRH agonist trigger, possible addition of metformin).
92,93
Menopause Several studies have suggested that AMH in conjunction with age may be able to predict the timing of menopause with reasonable accuracy in late reproductive-age women.
39-41
A recent report from the Study of Women's Health Across the Nation provided data on the use of AMH in predicting the final menstrual period (FMP) using the ultra-sensitive picoAMH assay, enabling especially accurate measurements at the lower end of detection. 94 At baseline, women were aged 42-52 years and blood was collected serially until the first visit after FMP. AMH was measured in a total of 1560 women. Women whose AMH values were 5-10 pg/mL had a 75% chance of having their FMP within 24 AE 3 months, while women with AMH levels of 25-!30 pg/mL had <2.5% chance of having their FMP within 2 years. 94 However, in a Dutch cohort study that included women of younger reproductive age (range 21-46 years), while AMH was predictive for age at natural menopause, the prediction intervals were broad and extreme ages at menopause could not be predicted. 95 The limited predictive ability of AMH for menopause in the general population may make this marker currently unsuitable for individualized counselling of women regarding their reproductive lifespan. Research is ongoing in pursuit of developing more accurate biomarker-based formulas for prediction of menopause timing.
Fertility preservation
With rising numbers of young girls and women being successfully cured by life-saving, but often gonadotoxic treatments, subsequent reproductive health has become a major quality-oflife issue, and the ability to predict which patients may lose their fertility or ovarian function as a result of treatment has become of increasing importance. AMH testing in young cancer patients both pretreatment and posttreatment has become a useful tool for assessment of iatrogenic damage to the ovarian follicular reserve inflicted by gonadotoxic ajog.org chemotherapy agents or pelvic irradiation, and may help in fertility preservation counselling and strategies. Chemotherapy and radiotherapy can both have deleterious effects on ovarian function and consequently AMH levels, with the extent of injury dependent on the patient's age, type of treatment, and treatment dose. 96 Studies have demonstrated that women with higher pretreatment AMH levels have higher postchemotherapy levels and display faster recovery rate in AMH levels once treatment had been completed. 97, 98 Importantly, 2 studies involving breast cancer patients provided prognostic tools by which clinicians can inform patients more precisely regarding ovarian function after chemotherapy using pretreatment AMH levels, with other important variables. 99, 100 The first prognostic tool demonstrated that all women, regardless of age, with AMH levels of <0.54 ng/mL will have amenorrhea posttreatment. 99 The second tool is a prognostic scoring system based on a patient's age, pretreatment AMH levels, and body mass index with 1 point awarded for each of age <40 years, AMH level >0.7 ng/mL, and body mass index >25 kg/m 2 . 100 The likelihood of, and time to, recovery of ovarian function after completion of chemotherapy improves with increasing number of points. For example, menses returned in 75% of women with 3 points by 160 days whereas only 25% of women with 0 points had a return of ovarian function by 221 days. 100 Since both of these prognostic systems were developed in breast cancer patients, and the systemic effects of differing forms of cancer and their treatment vary, it is not possible to generalize the results above to all cancers. Therefore, further research into different types of malignancies and treatment regimens is required to build up a panel of prognostic tools. Moreover, it should be emphasized that since the primary outcome of the research thus far has been posttreatment amenorrhea/premature ovarian insufficiency, there is not yet direct evidence that pretreatment AMH levels can predict subsequent fertility. This important outcome should be the focus of future investigations in this field.
Polycystic ovarian syndrome
It has been suggested that AMH plays an important role in the pathogenesis of PCOS. 101 Substantial evidence indicates that AMH correlates strongly with the severity of various hallmarks of PCOS, including polycystic ovarian morphology, hyperandrogenism, and oligo/anovulation. [102] [103] [104] [105] [106] [107] Moreover, elevated serum AMH concentrations are predictive of poor response to various treatments of PCOS including weight loss, ovulation induction, and laparoscopic ovarian drilling, while improvement in various clinical parameters following treatment is associated with serum AMH decline, further supporting an important role for AMH in the pathophysiology of this syndrome. 101 A cut-off of AMH >5.0 ng/mL has been shown to be highly diagnostic of PCOS (AUC 0.973, sensitivity 92%, specificity 97%), and suggested to be incorporated as a diagnostic criterion for this syndrome. 59, 60 Thus, AMH testing could be considered in the routine workup of PCOS patients and could aid in establishing the diagnosis, provide insight to the severity and potential treatment resistance, as well as alerting physicians to the increased risk of OHSS if ovulation induction is being considered. Table 3 summarizes the current indications for AMH testing.
Ovarian reserve screening for the general reproductive-age female population? It is estimated that approximately 10% of the general female population will undergo accelerated loss of ovarian reserve leading to loss of fertility from their mid30s and early menopause by age 45 years. 108, 109 In the past, this was of minimal concern from a public health standpoint since most women had completed their family plans by their mide30s. However, over the past 2 decades the average age of a mother at her first birth has steadily increased and is currently 30 years of age in the Western world, with a further 1 in 5 women not having commenced pregnancy attempt by 35 years of age. 110, 111 While some of these women have made a conscious decision not to have children, the majority still do want children but have simply not begun trying for a baby, often due to gaps of knowledge about agerelated fertility decline. 112, 113 Importantly, recent studies have shown that information about one's ovarian reserve would lead individuals to modify life choices. 112, 114 One study showed that among health care workers, if testing of the individual or individual's partner indicated DOR, 48% would try to have a child sooner, 21% would opt for oocyte cryopreservation, 7% would try to find a partner sooner, 7% would pursue adoption, and 3% would select embryo cryopreservation. Only 14% would not actively pursue treatment or make lifestyle changes. 114 Despite the consensus that AMH is an excellent marker of ovarian reserve, there is currently no agreement on the use of AMH to screen for ovarian reserve in the general, noninfertile population. 115, 116 Concerns raised by opponents of such testing are that a poor result does not definitively mean diminished chances of natural conception, 115, 116 while an abnormally low value may also lead to substantial anxiety with multiple potential negative consequences (eg, premature termination of education and career development to have children, seeking motherhood outside of a stable relationship). However, contrary to this argument, a recent study showed that bankers and nonbankers of oocytes have a surprising congruent relational status and reproductive choices, indicating that freezing oocytes does not appear to influence the life choices of the women. The study provides insights into the important psychological aspect of reassurance associated with preventive oocyte banking, expressed by high satisfaction after banking in combination with a decreased intention of ever using the eggs. 117 An important ethical Expert Reviews ajog.org consideration, however, is that oocyte banking is costly (w$10,000) and may not be affordable to many women identified as having low ovarian reserve by AMH screening. Proponents of ovarian reserve screening of the general population of reproductive-age women argue that it may offer several advantages. 118 First, women identified as having low ovarian reserve are thought to be at increased risk of early loss of fertility potential in the longer term. However, evidence in support of this argument is conflicting as 1 study found that women with low AMH (<0.7 ng/mL) have significantly decreased fecundability after adjusting for age, 119 while a more recent study reported that lower (<1.0 ng/mL) and higher (>3.5 ng/mL) AMH values were not associated with fecundability in unassisted conceptions in a cohort of fecund women with a history of 1 or 2 losses. 46 Second, women often disregard generic advice to avoid delaying conception >30 years of age, yet studies suggest that personalized risk assessment tools such as ovarian reserve testing can actually affect individual's family planning. 112, 114 Finally, it is reasonable to argue that women have a right, based on the ethical concept of autonomy, to be made aware of ovarian reserve screening, so that they themselves can determine if ovarian reserve testing is useful in assisting them with reproductive life planning. 118 However, before firm recommendations can be made, large longitudinal studies are needed to determine whether such screening strategies may be beneficial from a population health perspective.
Conclusions and recommendations
Evaluation of ovarian reserve can help identify patients who will have poor response or hyperresponse to ovarian stimulation for ART and individualize treatment protocols to achieve optimal response while minimizing safety risks. It may inform patients regarding their reproductive lifespan and menopausal timing, and also aid in counseling and treatment strategy planning of young female cancer patients receiving gonadotoxic therapy. In addition, it may aid in establishing the diagnosis of PCOS and provide insight into disease severity. Finally, ovarian reserve testing may be considered as a screening tool in selected populations of women for assisting in their reproductive life planning. The ideal ovarian reserve test should be convenient, be reproducible, display little if any intracycle and intercycle variability, and demonstrate high specificity to minimize the risk of wrongly diagnosing women as having DOR and accurately identify those at greatest risk of developing OHSS prior to fertility treatment. While there is currently no perfect ovarian reserve test, both AFC and AMH level have good predictive value and are superior to day-3 FSH. The convenience of untimed sampling, age-specific values, availability of an automated platform, and potential standardization of AMH assay make this test the preferred biomarker for the evaluation of ovarian reserve in most women. It is important to consider agespecific values when interpreting results and to remember that conditions such as PCOS and hormonal suppression can affect the values obtained.
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